The farm sold by Susana Giménez will become a cannabis megaproject

“La Tertulia”, the sumptuous farmhouse sold by Susana Giménez will become a mega-project for the cultivation, research and development of medicinal cannabis. It is the first center of its kind in the region, with the aim of positioning itself in the global trade of the iconic factory, as confirmed by the group of Argentinian businessmen who acquired the house.

The property consists of 110 hectares and is located 15 kilometers from Laguna Garzón and 60 kilometers from Punta del Este, in an exclusive area of ​​Uruguay. The estate is next door to another well-known estate, the Garzón winery, the wine development of the Bulgheroni family.

The purchase of the former house of Susana Giménez was made by YVY Life Sciences, a company in the Uruguayan and Argentinian capital dedicated to the research, cultivation and development of high-quality, sustainable cannabis products.

As announced, the transaction was promoted by Argentinian entrepreneurs. YVY Life Sciences is made up of two partners: the founder of InvertirOnline.com and former national deputy, Facundo Garretonand the FLA Ventures venture capital fund.

“We are honored to inherit this iconic property that will become the premier medical cannabis education and wellness center in Latin America.Garretón said.

The company indicated that “La Tertulia” fulfills all the conditions that were sought for this project, both in terms of strategic location and climatic conditions.

The aspiration of the entrepreneurs is to transform the luxurious farm into a sort of educational “hub” on regenerative agriculture and medicinal cannabis, which promotes knowledge of the plant and all its benefits. The megaproject also presupposes the possible opening of Uruguay to “cannabis tourism”. The expectation is to build a themed hotel with gastronomy and a cannabis wellness center for the whole region, “helping people with various medical conditions to achieve their general well-being,” they said in a statement. communicated.

An investment opportunity

YVY Life Sciences currently has 11 farms growing cannabis according to organic and sustainable cultivation standards. In 2020, the company completed its first pilot export to Europe for a total of 300 kilograms of dried flowers rich in cannabidiol (CBD), the main non-psychoactive component of the cannabis plant. In 2021, the intention is to send four tonnes of the component abroad.

The company was founded by Uruguayan Andrea Krell and South African Kevin Nafte, who currently serve as CEO and Strategic Director respectively. In 2018, the two decided to bet on the Latin American market for medical cannabis from Uruguay, promoting a pioneering business model in the region based on the creation of new jobs and agreements with small family farms.

The international context seems to have motivated the investment decision to buy “La Tertulia“. The coronavirus pandemic has generated an increase in demand for marijuana and its derivatives around the world. Even the election of the President of the United States, Joe biden, seems to bode well for the sector, as it would lay the foundations for a green wave in terms of legalization.

With this expectation, last January Garretón and FLA Ventures became majority shareholders of the company Blueberries Medical Corporation, also dedicated to the research, cultivation and development of cannabis-derived products. The company is listed on the Canadian Stock Exchange and has its main activities in Colombia. Currently, Garretón plays the role of president of Blueberries, while Sebastián Hochbaum, co-founder of FLA Ventures, is director of the company.

The global cannabis industry is worth nearly $ 150 billion, of which $ 95 billion depends on the commercialization of medical cannabis. At the Latin American level, a recent report by Latam Ban Partners pointed out that while the market value of cannabis will end at USD 168 million in 2020, this figure could quadruple by 2024, when it could reach 824 million dollars.

As part of the plans for 2021, YVY Life Sciences to Start Cultivating Genetics Rich in Tetrahydrocannabinol (THC), known to be the main psychoactive component of the cannabis plant. Investors expect local regulations to move forward to scale production as they plan to expand their line of organic and natural oils and cosmetics.

I continued to read: